These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Freeburg EM; Goyeneche AA; Telleria CM Int J Oncol; 2009 Mar; 34(3):743-55. PubMed ID: 19212679 [TBL] [Abstract][Full Text] [Related]
3. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM J Ovarian Res; 2014; 7():45. PubMed ID: 24795781 [TBL] [Abstract][Full Text] [Related]
4. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
6. Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin. Kapperman HE; Goyeneche AA; Telleria CM Cancer Cell Int; 2018; 18():185. PubMed ID: 30479564 [TBL] [Abstract][Full Text] [Related]
7. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Rose FV; Barnea ER Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817 [TBL] [Abstract][Full Text] [Related]
8. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Goyeneche AA; Seidel EE; Telleria CM Invest New Drugs; 2012 Jun; 30(3):967-80. PubMed ID: 21424700 [TBL] [Abstract][Full Text] [Related]
9. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Freeburg EM; Goyeneche AA; Seidel EE; Telleria CM Cancer Cell Int; 2009 Feb; 9():4. PubMed ID: 19222856 [TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
11. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688 [TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168 [TBL] [Abstract][Full Text] [Related]
13. PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells. Takai N; Ueda T; Nishida M; Nasu K; Narahara H Int J Mol Med; 2010 Jan; 25(1):97-103. PubMed ID: 19956907 [TBL] [Abstract][Full Text] [Related]
14. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells]. Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028 [TBL] [Abstract][Full Text] [Related]
15. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. Tieszen CR; Goyeneche AA; Brandhagen BN; Ortbahn CT; Telleria CM BMC Cancer; 2011 May; 11():207. PubMed ID: 21619605 [TBL] [Abstract][Full Text] [Related]
16. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. Dasari VR; Carey DJ; Gogoi R BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Reed E; Kohn EC; Sarosy G; Dabholkar M; Davis P; Jacob J; Maher M Semin Oncol; 1995 Jun; 22(3 Suppl 6):90-6. PubMed ID: 7541159 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines. Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]